The Management To Optimise Diabetes And MEtabolic Syndrome Risk Reduction Via Nurse-led Intervention (MODERN) Study
Funder
National Health and Medical Research Council
Funding Amount
$1,445,861.00
Summary
There is increasing recognition of society’s responsibility to provide effective and sustainable health care to the entire population and not just selected parts. This practical study will test the impact of a nurse-led, multidisciplinary prevention program to reduce the risk of future cardiovascular events in middle-aged individuals at a high risk of developing cardiovascular disease (CVD) living in regional Australia.
The GOOD NIGHT Project: A Sleep Intervention To Prevent Depression And Improve Cardiac Health In Adolescence
Funder
National Health and Medical Research Council
Funding Amount
$902,741.00
Summary
There is a pressing need for effective approaches to preventing depression during adolescence. The primary aim of the project is to assess whether a brief sleep intervention can prevent depression in vulnerable adolescents. Given that sleep interventions also encourage daytime activity, which when combined with improved sleep has potential benefits for cardiovascular health, the secondary aim is to test whether the sleep intervention improves early indicators of cardiovascular risk.
Reducing Disparities In Heart Disease-Related Morbidity And Mortality: Optimising Prevention And Management
Funder
National Health and Medical Research Council
Funding Amount
$826,854.00
Summary
Heart disease contributes to a large but potentially preventable burden of death and disability. This burden is uneven with particularly vulnerable/at risk groups - including those living in regional areas and developing countries, Indigenous Australians and older patients with chronic heart disease. Prof. Simon Stewart will lead national/international collaborations to undertake innovative, multidisciplinary, prevention and disease management programs to reduce the impact and burden of heart di ....Heart disease contributes to a large but potentially preventable burden of death and disability. This burden is uneven with particularly vulnerable/at risk groups - including those living in regional areas and developing countries, Indigenous Australians and older patients with chronic heart disease. Prof. Simon Stewart will lead national/international collaborations to undertake innovative, multidisciplinary, prevention and disease management programs to reduce the impact and burden of heart disease in these vulnerable groups.Read moreRead less
Centre Of Research Excellence In Cardiovascular Outcomes Improvement
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
Quality, safety and the effectiveness of providing prevention and treatments to those with cardiovascular disease is the focus of research of the CRE in Cardiovascular Outcomes Improvement. Utilizing data derived from clinical registries and large patient databases of patients receiving various treatments for heart problems, we will investigate what factors are important in delivering cost-effective favorable outcomes. The centre will train future leaders in cardiovascular research focusing on
Randomised Double-blind Placebo-controlled Trial Of Aspirin In Primary Prevention Of CVD Events Or Dementia In The Aged.
Funder
National Health and Medical Research Council
Funding Amount
$3,532,500.00
Summary
The single most important risk factor for cardiovascular disease is age. All men aged 75 years have a 10-15% risk of having a stroke or heart attack in the next 5 years. Low dose aspirin has been shown to prevent further strokes and heart attacks in people who have already had one. It has been also shown to protect people who have not had a heart attack or stroke but who are at increased risk. Given that the elderly are at increased risk why do we need to do a trial in this particular group? The ....The single most important risk factor for cardiovascular disease is age. All men aged 75 years have a 10-15% risk of having a stroke or heart attack in the next 5 years. Low dose aspirin has been shown to prevent further strokes and heart attacks in people who have already had one. It has been also shown to protect people who have not had a heart attack or stroke but who are at increased risk. Given that the elderly are at increased risk why do we need to do a trial in this particular group? The reason is that relatively few elderly patients were included in the previous prevention trials. Also while the elderly may have the most to gain from treatment, they also have the most to lose because they are more likely to suffer from side-effects. Aspirin prevents heart attacks by stopping clots forming in blood vessels. This also means that people taking it have an increased tendency to bleed. Thus though it may prevent strokes due to clots it may also increase the risk of strokes caused by bleeding. Bleeding from the gut is another major problem as aspirin tends to erode the lining of the stomach. Minor bleeding from the gut can also lower blood oxygen carrying capacity which may exacerbate other diseases associated with ageing, e.g. heart failure. Dementia may be caused by repeated clots in small or large vessels. Dementia is a particular problem in the elderly affecting 10% of 85 year olds. It is a major cause of loss of quality of life and a significant cost to the community. Aspirin may reduce the progression of such a disease leading to a maintained quality of life (QOL) for individuals and their families. As our age increases our years of life remaining decreases. This is self-evident. Thus the potential to add years to life reduces and the potential of diseases to adversely affect quality of life becomes more important. Thus it may be more important to prevent a nonfatal stroke that leads to institutionalisation than a fatal stroke. Hence QOL will be assessed.Read moreRead less
The identification, prevention and management of chronic disease risk factors and understanding impact on clinical outcomes is fundamental to improving health and well-being. The program of work encapsulated in this application utilises a number of research methods to advance our understanding and provide new directions for cardiovascular disease prevention and management.
The Central Australian Heart Protection Study: A Randomised Trial Of Nurse-Led, Family Based Secondary Prevention Of Acute Coronary Syndromes
Funder
National Health and Medical Research Council
Funding Amount
$1,923,630.00
Summary
Despite the high burden of cardiovascular diseases among Indigenous Australians, few intervention trials have sought to evaluate novel approaches to reducing differential outcomes in this vulnerable group. The Central Australian Heart Protection Study seeks to test the effectiveness of a nurse-led, family based education and assessment program in reducing the incidence of poor outcomes in indigenous and non-indigenous patient’s following an Acute Coronary Syndrome (ACS).
Associations Between Urban Nature And Cardiovascular Disease Risk
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Cardiovascular disease (CVD) is the leading cause of death in Australia. Urban nature (e.g. greenness, water, species diversity) is likely to protect against CVD, yet researchers lack knowledge about how this occurs. This project will develop new methods to measure urban nature and examine the relationships with different CVD risk factors (e.g. physical activity, air quality). The results of this project will inform urban planning policy, and help to create healthy cities that reduce CVD.